FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / J Vet Pharmacol Ther / Plasma and Urinary Elimination Profiles of Medetomidine Meta...
Journal of veterinary pharmacology and therapeutics2026; doi: 10.1111/jvp.70063

Plasma and Urinary Elimination Profiles of Medetomidine Metabolites in Horses for the Purpose of Doping and Medication Control.

Abstract: Medetomidine, an α₂-adrenergic agonist, is widely used as a sedative in horses. While its pharmacological effects are established, limited data exist on elimination of its metabolites, 3'-hydroxy medetomidine (HMD) and 3'-carboxy medetomidine (CMD), which are of regulatory interest. HMD is currently targeted in plasma and urine under International Screening Limits (ISLs) established by the International Federation of Horseracing Authorities (IFHA). In this study, seven Thoroughbreds received 6.3 μg/kg of medetomidine intravenously. Blood and urine were collected for 96 h and analyzed by LC-MS/MS after solid-phase extraction with and without enzymatic hydrolysis. Parent drug was detectable in plasma up to 4 h but absent in urine. HMD was quantifiable in plasma to 48 h and urine to 72 h, while CMD, with a distinct profile, was measurable in plasma to 32 h and urine to 72 h. Based on the ISLs, the detection times (DTs) for both plasma and urine were 48 h. Pharmacokinetic modeling estimated clearance at 2.15 L/h/kg and steady-state distribution volume at 1.90 L/kg. These findings show rapid clearance of medetomidine and extended metabolite excretion. The DT of HMD aligns with loss of pharmacological effect, supporting current ISLs and reinforcing the rationale for targeting HMD, with CMD providing supplementary regulatory insight.
© 2026 John Wiley & Sons Ltd.
Get Full Text
Publication Date: 2026-03-05 PubMed ID: 41785163DOI: 10.1111/jvp.70063Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Cite This Article

APA
Minamijima Y, Kuroda T, Maeda Y, Narita S, Yamashita S, Yamada M. (2026). Plasma and Urinary Elimination Profiles of Medetomidine Metabolites in Horses for the Purpose of Doping and Medication Control. J Vet Pharmacol Ther. https://doi.org/10.1111/jvp.70063

Publication

Journal of veterinary pharmacology and therapeutics
ISSN: 1365-2885
NlmUniqueID: 7910920
Country: England
Language: English

Researcher Affiliations

Minamijima, Yohei
  • Laboratory of Racing Chemistry, Utsunomiya, Tochigi, Japan.
Kuroda, Taisuke
  • Equine Research Institute, Japan Racing Association, Shimotsuke, Tochigi, Japan.
  • Graduate School of Agriculture, Tokyo University of Agriculture and Technology, Fuchu, Japan.
Maeda, Yoshimasa
  • Equine Veterinary Clinic, Horse Racing School, Japan Racing Association, Shiroi, Chiba, Japan.
Narita, Shoichi
  • Equine Veterinary Clinic, Horse Racing School, Japan Racing Association, Shiroi, Chiba, Japan.
Yamashita, Shozo
  • Laboratory of Racing Chemistry, Utsunomiya, Tochigi, Japan.
Yamada, Masayuki
  • Laboratory of Racing Chemistry, Utsunomiya, Tochigi, Japan.

Grant Funding

  • Laboratory of Racing Chemistry
  • Japan Racing Association

References

This article includes 21 references
  1. Committee for Veterinary Medicinal Products. 2026. “Detomidine Summary Report.” https://www.ema.europa.eu/en/documents/mrl‐report/detomidine‐summary‐report‐committee‐veterinary‐medicinal‐products_en.pdf.
  2. Duhamel, M. C., E. Troncy, and F. Beaudry. 2010. “Metabolic Stability and Determination of Cytochrome P450 Isoenzymes' Contribution to the Metabolism of Medetomidine in Dog Liver Microsomes.” Biomedical Chromatography 24, no. 8: 868–877.
  3. Durney, P., J. L. Kahoud, T. Warrick‐Stone, et al. 2025. “Biochemical Identification and Clinical Description of Medetomidine Exposure in People Who Use Fentanyl in Philadelphia, PA.” International Journal of Molecular Sciences 26, no. 14: 6715.
  4. England, G. C., and K. W. Clarke. 1996. “Alpha 2 Adrenoceptor Agonists in the Horse—A Review.” British Veterinary Journal 152, no. 6: 641–657.
  5. Granados, M. M., F. Medina‐Bautista, R. Navarrete‐Calvo, et al. 2025. “Population Pharmacokinetics and Clinical Evaluation of Intravenous Acetaminophen and Its Metabolites in Andalusian Horses.” Veterinary Journal 312: 106357.
  6. Grimsrud, K. N., S. Ait‐Oudhia, B. P. Durbin‐Johnson, et al. 2015. “Pharmacokinetic and Pharmacodynamic Analysis Comparing Diverse Effects of Detomidine, Medetomidine, and Dexmedetomidine in the Horse: A Population Analysis.” Journal of Veterinary Pharmacology and Therapeutics 38, no. 1: 24–34.
  7. Grimsrud, K. N., K. R. Mama, E. P. Steffey, and S. D. Stanley. 2012. “Pharmacokinetics and Pharmacodynamics of Intravenous Medetomidine in the Horse.” Veterinary Anaesthesia and Analgesia 39, no. 1: 38–48.
  8. Hobo, S., H. Aida, and K. Yoshida. 1995. “Assessment of the Sedative Effect of Medetomidine and Determination of Its Optimal Dose in Thoroughbred Horses.” Journal of Veterinary Medical Science 57, no. 3: 507–510.
  9. IFHA. 2026a. https://ifhaonline.org/Default.asp?section=IABRW&area=1.
  10. IFHA. 2026b. https://ifhaonline.org/Default.asp?section=IABRW&area=6.
  11. IFHA. 2026c. “Publication of Detection Times on the IFHA Website.” https://www.ifhaonline.org/resources/DetectionTimes.pdf.
  12. Medbullets. 2026. “Medbullets Pharmacology: Phase I vs Phase II Metabolism.” https://step1.medbullets.com/pharmacology/107006/phase‐i‐vs‐phase‐ii‐metabolism.
  13. Minamijima, Y., T. Kuroda, T. Kamiya, et al. 2024. “Evaluation of Plasma and Urine Pharmacokinetics of Tranexamic Acid for Equine Medication Control.” Journal of Veterinary Pharmacology and Therapeutics 47, no. 1: 21–27.
  14. Salonen, J. S., and M. Eloranta. 1990. “Biotransformation of Medetomidine in the Rat.” Xenobiotica 20, no. 5: 471–480.
  15. Tokushige, H., M. Araki, K. Kusano, et al. 2019. “A Retrospective Comparison of Induction With Thiopental/Guaifenesin and Propofol/Ketamine in Thoroughbred Racehorses Anesthetized With Sevoflurane and Medetomidine During Arthroscopic Surgery.” Journal of Equine Science 30, no. 2: 25–31.
  16. Toutain, P. L., and V. Lassourd. 2002. “Pharmacokinetic/Pharmacodynamic Approach to Assess Irrelevant Plasma or Urine Drug Concentrations in Postcompetition Samples for Drug Control in the Horse.” Equine Veterinary Journal 34, no. 3: 242–249.
  17. ul Amin Mohsin, N., M. Farrukh, S. Shahzadi, and M. Irfan. 2024. Drug Metabolism: Phase I and Phase II Metabolic Pathways. IntechOpen.
  18. Yamashita, K. 2010. “Clinical Anesthesia in Horses.” Journal of the Japan Society of Clinical Anesthesiologists 30, no. 2: 181–188. https://www.jstage.jst.go.jp/article/jjsca/30/2/30_2_181/_article/‐char/en.
  19. Yamashita, K., M. S. Hoque, K. Yonezawa, J. Abe, Y. Izumisawa, and T. Kotani. 1994. “Sedative and Analgesic Effects of Medetomidine in Horses.” Japanese Journal of Veterinary Anesthesia and Surgery 25, no. 4: 95–100.
  20. Yamashita, K., K. Kishihara, S. Haramaki, et al. 1999. “Sedative Effects of Medetomidine, Detomidine, and Xylazine in Horses.” Journal of the Japan Veterinary Medical Association 52, no. 8: 498–503.
  21. Yamashita, K., W. W. Muir III, S. Tsubakishita, et al. 2002. “Clinical Comparison of Xylazine and Medetomidine for Premedication of Horses.” Journal of the American Veterinary Medical Association 221, no. 8: 1144–1149.

Citations

This article has been cited 0 times.
Subscribe to our newsletter
Join 99,021 horse owners like you who receive our email updates on horse health and nutrition.